1Q21 BUSINESS INTRODUCTION

- IR Book (1Q20, Korean)C O P Y R I G H T © D A E W O N P H A R M A C E U T I C A L C O . , L T D . 2 0 2 1 . A L L R I G H T S R E S E R V E D .
1 Q 2 1 B U S I N E S S I N T R O D U C T I O N
INVESTOR RELATIONS (1Q21)DISCLAIMER
( )
2 Graphics : Freepik et al., 2020. Fonts : Google Inc., 2020. Used under the SIL Open Font License v1.1.
INVESTOR RELATIONS (1Q21)
1. 1Q21
3 [1] OTC : Over the Counter Drug [2] CHC : Consumer Health Care [3] : DW-4902( ), ( ), ( )
INVESTOR RELATIONS (1Q21)2. _
4 [1] ( 2019 3,178 , 2020 3,085 ), ( 2019 351 , 2020 237 ) [2] : , 2020
2020 19 2021 19
6 (2016~) ENT 64% (2019 )
ENT,
13.0% M/S (2019) 2 9.8%, 3 8.0%
,
(GH), (CMO) 100 ,
623 (+8.4%)
705 (+13.2%)
756 (+7.3%)
800 (+5.7%)
640 (+4.8%)
698 (+9.1%)
781 (+11.9%)
742 (-4.9%)
648 (+18.3%)
638 (-1.6%)
749 (+17.4%)
753 (+0.5%)
723 (+11.0%)
795 (+10.0%)
867 (+9.1%)
769 (-11.3%)
1Q 2Q 3Q 4Q
2020 1 ,
8 [1] [2] GERD : Gastroesophageal Reflux Disease (acid-reflux)
( , , ) ( 100 : 2018 5 2019 [1] 8 2020 8 2021 8~9 )
/ 2018 2019 2020
[ : ]
1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 q-q% y-y%
66 69 68 84 64 62 68 70 64 -8.6% 0.0%
55 57 37 74 61 21 24 53 35 -34.0% -42.6%
32 29 35 40 35 39 39 38 36 -5.3% 2.9%
30 32 32 32 32 35 45 28 37 32.1% 15.6%
26 25 28 34 29 30 30 30 27 -10.0% -6.9%
20 21 25 25 26 27 30 30 29 -3.3% 11.5%
28 27 27 26 26 26 26 24 25 4.2% -3.8%
22 21 23 22 23 24 25 24 26 8.3% 13.0%
22 21 21 21 22 22 22 20 20 0.0% -9.1%
301 302 296 358 318 286 309 317 299 -5.7% -6.0%
756 781 749 867 800 742 753 768 743 -3.3% -7.1%
39.8% 38.7% 39.5% 41.3% 39.8% 38.5% 41.0% 41.3% 40.2% - -
INVESTOR RELATIONS (1Q21)
10.0% 10.1% 10.9% 11.0%
(%)
, R&D
5. R&D Pipelines _
10 [SAD, MAD] (Single Ascending Dose), (Multiple Ascending Dose) [LH] (luteinizing hormone) : ,
DW-4301 : , 2 IND DW-4902 : ( ) 2 IND , ( ) 2a IND
DW-4301 DW-4902
INVESTOR RELATIONS (1Q21)5. R&D Pipelines _
11 [1] glucagon-like peptide 1, / [2] LFA-1 ICAM-1 LFA-1 [LFA-1] lymphocyte function-associated antigen 1, / [ICAM-1] intercellular adhesion molecule,
(GLP-1 ) : (Rybelsus ) BA & ( ) :
INVESTOR RELATIONS (1Q21)6. Summary
12 [1] 50 15 , 5yr CAGR 2 (39.7%) [2] 20%, 20%, 18%, 15%, 27%
ENT 1 , 1 , 4 [1]
R&D
31%0%
2014 2018
5.7%
8.4%
11.3%
(%)
630 - - - -
[ : ] [ : ]
2018 2019 2020 1Q20 1Q21 y-y%
286,652 315,309 306,358 79,976 74,296 (7.10%)
121,164 136,357 141,093 35,386 35,942 1.57% [1] 125,467 132,711 126,511 31,287 38,309 22.44%
30,745 35,997 25,276 10,343 (2,179) (121.07%)
31,209 35,492 23,726 9,777 (1,754) (117.94%)
23,286 27,000 17,487 7,331 (8,136) (210.98%)
2018 2019 2020 1Q20 1Q21 y-y%
42.3% 43.2% 46.1% 44.2% 48.4% 9.50% [1] 43.8% 42.1% 41.3% 42.8% 51.6% 20.56%
10.7% 11.4% 8.3% 12.9% -
10.9% 11.3% 7.7% 12.2% -
8.1% 8.6% 5.7% 9.2% -
1Q20 3Q20 4Q20 1Q21 q-q%
79,976 75,282 76,949 74,296 (3.45%)
35,386 35,456 35,509 35,942 1.22% [1] 31,287 34,353 26,119 38,309 46.67%
10,343 5,473 1,844 (2,179) (218.17%)
9,777 5,035 3,131 (1,754) (156.02%)
7,331 3,453 2,409 (8,136) (437.73%)
( )
4Q19 3Q20 4Q20 1Q21 q-q%
42.8% 43.3% 46.1% 48.4% 4.99% [1] 45.0% 45.2% 41.3% 51.6% 24.94%
12.1% 11.6% 2.4% (2.9%) (134.94%)
12.0% 11.7% 4.1% (2.4%) (131.17%)
9.7% 8.8% 3.1% (11.0%) (292.98%)
( )
[ : ] [ : ]
[ : %] [ : %]
19 [ ] , ( ), 2020 8
PIPELINES INDICATIONS 2020 2021 2022 2023 2024
3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q
IMD DW-2802
IMD DW-1502
IMD DW-1809
PIPELINES INDICATIONS 2020 2021 2022 2023 2024
3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q
NCE DW-4301
NCE DW-4902
2019 31,511 27,124 4,387 357 27,225 799
2018 27,796 24,208 3,587 357 25,596 685
1996 2
0
100
200
2 0 1 6 2 0 1 7 2 0 1 8 2 0 1 9 2 0 2 0 3 Q
Top 3
[ : %]